Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)

BACKGROUND: The efficacy of current adjuvant chemotherapy for gastric adenocarcinoma/gastroesophageal junction adenocarcinoma (GA/GEJA) leaves much to be desired. ctDNA could serve as a potential marker to identify patients who are at higher risk of recurrence. Reinforcing standard adjuvant chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yizhang, Zhang, Jiaguang, Han, Gaohua, Tang, Jie, Guo, Fen, Li, Wei, Xie, Li, Xu, Hao, Zhang, Xinyi, Tian, Yitong, Pan, Lanlan, Shu, Yongqian, Ma, Ling, Chen, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644233/
https://www.ncbi.nlm.nih.gov/pubmed/38022553
http://dx.doi.org/10.3389/fimmu.2023.1232858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644233/
https://www.ncbi.nlm.nih.gov/pubmed/38022553
http://dx.doi.org/10.3389/fimmu.2023.1232858

Ejemplares similares